Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

504
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
504
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

641
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
641
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

501
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
501
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

184
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
184
Acute Pancreatitis I: Introduction01:27

Acute Pancreatitis I: Introduction

910
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
910
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.6K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.6K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence.

Alimentary pharmacology & therapeutics·2026
Same author

Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective.

The American journal of gastroenterology·2026
Same author

Can we cure primary biliary cholangitis?

Current opinion in immunology·2026
Same author

Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Seronegative Autoimmune Hepatitis in Adults Is a Rare Entity Often Obscured by Suboptimal Diagnostic Assessment.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

From science to public health impact: Enacting the recommendations of the EASL-Lancet Commission on liver health in Europe.

Journal of hepatology·2026

Video Experimental Relacionado

Updated: Nov 26, 2025

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

537

Colangitis biliar primaria

Ana Lleo1, Giu-Qiang Wang2, Merrill Eric Gershwin3

  • 1Department of Biomedical Sciences, Humanitas University, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.

Lancet (London, England)
|December 14, 2020
PubMed
Resumen
Este resumen es generado por máquina.

La colangitis biliar primaria (CBP) es una enfermedad hepática autoinmune que afecta principalmente a las mujeres. El tratamiento se centra en el ácido ursodeoxicólico, con ácido obeticólico como terapia adicional para los que no responden, mientras que el manejo de los síntomas es crucial.

Más Videos Relacionados

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.2K

Videos de Experimentos Relacionados

Last Updated: Nov 26, 2025

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

537
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.2K

Área de la Ciencia:

  • Hepatología
  • Enfermedades autoinmunes
  • Gastroenterología

Sus antecedentes:

  • La colangitis biliar primaria es una enfermedad hepática autoinmune crónica que afecta predominantemente a las mujeres.
  • Se caracteriza por la destrucción linfocítica de los conductos biliares pequeños, lo que lleva a la colestasis y la fibrosis.
  • La etiología implica daño inmunológico, predisposición genética y factores ambientales.

Objetivo del estudio:

  • Revisar la comprensión y el tratamiento actuales de la colangitis biliar primaria.
  • Para discutir las estrategias terapéuticas establecidas y emergentes.
  • Destacar la importancia de la estratificación del riesgo y el control de los síntomas.

Principales métodos:

  • Revisión de la literatura sobre la patogénesis, el diagnóstico y el tratamiento de la colangitis biliar primaria.
  • Análisis de las directrices actuales de tratamiento y datos de ensayos clínicos.
  • Enfoque en los resultados informados por el paciente, incluyendo prurito y fatiga.

Principales resultados:

  • El ácido ursodeoxicólico es el tratamiento primario para la colestasis.
  • El ácido obeticólico sirve como terapia adicional para los pacientes con respuesta inadecuada.
  • Bezafibrate y los agentes en investigación representan opciones de tratamiento alternativas y futuras.
  • La estratificación del riesgo utiliza las características basales y los marcadores de lesión hepática (bilirrubina, ALP).

Conclusiones:

  • El tratamiento eficaz de la CBP requiere abordar tanto la progresión de la enfermedad como los síntomas del paciente.
  • Los enfoques de tratamiento personalizados son esenciales para optimizar los resultados.
  • La investigación en curso tiene como objetivo desarrollar nuevas terapias para la CBP.